Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: OM-174; OM-174-DP

Latest Information Update: 09 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OM Pharma
  • Developer Vifor Pharma
  • Class Adjuvants; Antineoplastics; Glycoconjugates
  • Mechanism of Action Immunostimulants; Macrophage stimulants; Toll-like receptor 4 modulators; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 May 2014 Discontinued - Phase-I for Cancer in Switzerland (Parenteral)
  • 24 Feb 2011 Phase-Ib development is ongoing in Switzerland
  • 09 Sep 2009 OM Pharma has been acquired and merged into Vifor Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top